Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_assertion type Assertion NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_head.
- NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_assertion description "[In this study, we investigated the cytolytic activity of peripheral blood T-cells (PBT) obtained from nine patients with primary lung cancer treated by surgical adjuvant adoptive immunotherapy (AIT) with lymphokine-activated killer cells and low-dose recombinant interleukin 2 at the time of rebound lymphocytosis (24-48 h after AIT).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_provenance.
- NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_assertion evidence source_evidence_literature NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_provenance.
- NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_assertion SIO_000772 1997188 NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_provenance.
- NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_assertion wasDerivedFrom befree-2016 NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_provenance.
- NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_assertion wasGeneratedBy ECO_0000203 NP780052.RA-lM3tddqTHMa07ZFZe-uZwgVuLNvr1lpe_EzC7eglEU130_provenance.